Genome editing is a scientific way of modifying the DNA of many organisms such as plants, bacteria, and animals. By making changes in DNA, it leads to a change in physical traits, like eye color, and disease risk. Scientists use different technologies to carry out to remove, add, or replace the DNA where it was edited.CRISPR Technology is the most powerful tool for editing genomes which allows researchers to easily alter DNA sequences and modify gene function. CRISPR technology is used for many applications include correcting genetic defects, treating and preventing the spread of diseases and improving crops. Additionally, increasing clinical trials on CRISPR is one of the key factor fueling the global genome editing market.
For instance, in September 2018, Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics, jointly introduced a trial of an experimental CRISPR-Cas9 therapy for the blood disorder ß-thalassemia.
In August 2018, CRISPR Therapeutics and Vertex Pharmaceuticals sponsored the first human trial of gene editing technology. The trial has taken place in Germany. CTX001 is being developed for the blood disorders sickle cell disease and beta thalassemia. CTX001 uses CRISPR gene-editing ex vivo which is, outside the body.
The global genome editing market was valued at US$ 3,213.2 million in 2018 and is expected to witness a CAGR of 14.1% over the forecast period (2019–2026).
Research Funding for genome editing:
As genome editing has gained trust among most of the major players, there has been a significant contribution and funding in the year 2018, for instances, in October 2018, Synthego, a leading genome engineering innovation company, has received $110 million funds to accelerate CRISPR capabilities for rapid and precise genome engineering in applications such as cell and gene therapies.
Know more insights at: [URL]https://www.datamintelligence.com/research-report/genome-editing-market/[/URL]
Recent Product launches and critical developments:
For instance, on 25th January 2019, Vertex regained limited rights of two DNA-dependent protein kinase (DNA-PK) inhibitors from Merck. Merck licensed the drugs and other assets for $230 million upfront earlier and has now granted Vertex the right to use them in specific gene-editing applications. With such developments, researchers used DNA-PK inhibitors to modulate mechanisms that repair DNA breaks and thereby improve CRISPR/Cas9 genome editing.
On 21st January 2019, Horizon Discovery extended its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension would meet the requirements of immunology-based research in drug discovery, enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
Request free sample with premium insights now : [URL]whttps://www.datamintelligence.com/research-report/genome-editing-market/[/URL]